These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 22925456)

  • 21. Comparison of CLSI 2009, CLSI 2010 and EUCAST cephalosporin clinical breakpoints in recent clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca from the SMART Global Surveillance Study.
    Hawser SP; Badal RE; Bouchillon SK; Hoban DJ; Hsueh PR
    Int J Antimicrob Agents; 2010 Sep; 36(3):293-4. PubMed ID: 20598511
    [No Abstract]   [Full Text] [Related]  

  • 22. Do different susceptibility breakpoints affect the selection of antimicrobials for treatment of uncomplicated cystitis?
    Schito GC; Gualco L; Naber KG; Botto H; Palou J; Mazzei T; Marchese A
    J Chemother; 2010 Oct; 22(5):345-54. PubMed ID: 21123159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy.
    Riou M; Carbonnelle S; Avrain L; Mesaros N; Pirnay JP; Bilocq F; De Vos D; Simon A; Piérard D; Jacobs F; Dediste A; Tulkens PM; Van Bambeke F; Glupczynski Y
    Int J Antimicrob Agents; 2010 Dec; 36(6):513-22. PubMed ID: 20926262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of antimicrobial susceptibility interpretation among Enterobacteriaceae using CLSI and EUCAST breakpoints.
    Suravaram S; Hada V; Ahmed Siddiqui I
    Indian J Med Microbiol; 2021 Jul; 39(3):315-319. PubMed ID: 34016471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
    Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
    J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Performance of EUCAST and CLSI approaches for co-amoxiclav susceptibility testing conditions for clinical categorization of a collection of Escherichia coli isolates with characterized resistance phenotypes.
    Díez-Aguilar M; Morosini MI; López-Cerero L; Pascual Á; Calvo J; Martínez-Martínez L; Marco F; Vila J; Ortega A; Oteo J; Cantón R
    J Antimicrob Chemother; 2015 Aug; 70(8):2306-10. PubMed ID: 25900161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results from the Survey of Antibiotic Resistance (SOAR) 2011-13 in Turkey.
    Soyletir G; Altinkanat G; Gur D; Altun B; Tunger A; Aydemir S; Kayacan C; Aktas Z; Gunaydin M; Karadag A; Gorur H; Morrissey I; Torumkuney D
    J Antimicrob Chemother; 2016 May; 71 Suppl 1(Suppl 1):i71-83. PubMed ID: 27048584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results from the Survey of Antibiotic Resistance (SOAR) 2015-17 in Turkey: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
    Torumkuney D; Tunger A; Sancak B; Bıçakçıgil A; Altun B; Aktas Z; Kayacan C; Morrissey I
    J Antimicrob Chemother; 2020 Apr; 75(Suppl 1):i88-i99. PubMed ID: 32337598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Results from the Survey of Antibiotic Resistance (SOAR) 2016-17 in Ukraine: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
    Torumkuney D; Bratus E; Yuvko O; Pertseva T; Morrissey I
    J Antimicrob Chemother; 2020 Apr; 75(Suppl 1):i100-i111. PubMed ID: 32337596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results from the Survey of Antibiotic Resistance (SOAR) 2015-17 in Pakistan: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
    Torumkuney D; Anwar S; Nizamuddin S; Malik N; Morrissey I
    J Antimicrob Chemother; 2020 Apr; 75(Suppl 1):i76-i87. PubMed ID: 32337594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing the similarity of antimicrobial resistance phenotypes among fecal Escherichia coli isolates from two aggregated occupational cohorts of humans versus swine using cluster analysis and multivariate statistics.
    Alali WQ; Scott HM; Norby B
    Prev Vet Med; 2010 Apr; 94(1-2):77-83. PubMed ID: 20022646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial resistance to cefotaxime and ertapenem in Enterobacteriaceae: the effects of altering clinical breakpoints.
    Liu PY; Shi ZY; Tung KC; Shyu CL; Chan KW; Liu JW; Wu ZY; Kao CC; Huang YC; Lin CF
    J Infect Dev Ctries; 2014 Mar; 8(3):289-96. PubMed ID: 24619258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity in vitro of twelve antibiotics against clinical isolates of extended-spectrum beta-lactamase producing Escherichia coli.
    Sorlózano A; Gutiérrez J; Romero JM; de Dios Luna J; Damas M; Piédrola G
    J Basic Microbiol; 2007 Oct; 47(5):413-6. PubMed ID: 17910106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gentamicin susceptibility in Escherichia coli related to the genetic background: problems with breakpoints.
    Jakobsen L; Sandvang D; Jensen VF; Seyfarth AM; Frimodt-Møller N; Hammerum AM
    Clin Microbiol Infect; 2007 Aug; 13(8):830-2. PubMed ID: 17501975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial resistance to benzylpenicillin in invasive pneumococcal disease in Belgium, 2003-2010: the effect of altering clinical breakpoints.
    Goossens MC; Catry B; Verhaegen J
    Epidemiol Infect; 2013 Mar; 141(3):490-5. PubMed ID: 22677465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Bishara J; Livne G; Ashkenazi S; Levy I; Pitlik S; Ofir O; Lev B; Samra Z
    Isr Med Assoc J; 2005 May; 7(5):298-301. PubMed ID: 15909461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria.
    Chen YH; Hsueh PR; Badal RE; Hawser SP; Hoban DJ; Bouchillon SK; Ni Y; Paterson DL
    J Infect; 2011 Apr; 62(4):280-91. PubMed ID: 21382411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Change of antibiotic susceptibility testing guidelines from CLSI to EUCAST: influence on cumulative hospital antibiograms.
    Wolfensberger A; Sax H; Weber R; Zbinden R; Kuster SP; Hombach M
    PLoS One; 2013; 8(11):e79130. PubMed ID: 24223893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Limited diversity in the gene pool allows prediction of third-generation cephalosporin and aminoglycoside resistance in Escherichia coli and Klebsiella pneumoniae.
    Ginn AN; Zong Z; Wiklendt AM; Thomas LC; Merlino J; Gottlieb T; van Hal S; Harkness J; Macleod C; Bell SM; Leroi MJ; Partridge SR; Iredell JR
    Int J Antimicrob Agents; 2013 Jul; 42(1):19-26. PubMed ID: 23706544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The critical influence of the intermediate category on interpretation errors in revised EUCAST and CLSI antimicrobial susceptibility testing guidelines.
    Hombach M; Böttger EC; Roos M
    Clin Microbiol Infect; 2013 Feb; 19(2):E59-71. PubMed ID: 23210931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.